Rucaparib camsylate

Drug Overview:

Rucaparib camsylate is an oral, small-molecule poly (ADP-ribose) polymerase (PARP) inhibitor used as a targeted therapy for specific types of advanced ovarian, prostate, and other cancers associated with homologous recombination deficiency (HRD).

• Generic Name: Rucaparib camsylate
• US Brand Name: Rubraca®
• Drug Class: Poly (ADP-ribose) Polymerase (PARP) Inhibitor
• Route of Administration: Oral (tablet)
• FDA Approval Status: Approved for:

1. Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
2. Treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies.
3. Treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.

What Is It and How Does It Work? (Mechanism of Action):

Rucaparib is a targeted therapy that exploits a specific vulnerability in cancer cells with deficient DNA repair machinery, a concept known as “synthetic lethality.”

• Molecular Target: Rucaparib potently inhibits the enzymes poly (ADP-ribose) polymerase 1 and 2 (PARP1 and PARP2). PARP enzymes are critical for the repair of single-strand DNA breaks through the base excision repair pathway.
• Cellular Impact: By inhibiting PARP, rucaparib traps the PARP enzyme on DNA and prevents the repair of routine single-strand breaks. These unrepaired breaks stall DNA replication forks and collapse into highly cytotoxic double-strand breaks during DNA replication.
• Result: In healthy cells, double-strand breaks are efficiently repaired by the homologous recombination repair (HRR) pathway, which involves proteins like BRCA1 and BRCA2. Cancer cells with HRR deficiency (e.g., due to BRCA1/2 mutations) cannot use this error-free repair method. The accumulation of unrepaired double-strand breaks in these HRD cells leads to genomic instability and catastrophic cell death (apoptosis).
• Targeted Therapy Characteristic: As a PARP inhibitor, rucaparib is a “smart drug” that selectively kills cancer cells with pre-existing DNA repair defects while largely sparing healthy cells with intact repair pathways.

FDA Approved Clinical Indications:

Oncological Uses:

• Ovarian, Fallopian Tube, and Primary Peritoneal Cancer:
  • Maintenance Treatment: For patients in response to platinum-based chemotherapy.
  • Treatment: For patients with deleterious BRCA mutations who have received two or more chemotherapies.
• Prostate Cancer: Treatment of patients with deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane.

Non-Oncological Uses:

• There are currently no FDA-approved non-oncological indications for rucaparib.

Dosage and Administration Protocols:

Rucaparib is taken orally, typically twice daily, and must be continued until disease progression or unacceptable toxicity.

Renal and Hepatic Dose Adjustments

• Renal Impairment: No dosage adjustment for mild or moderate impairment. Not recommended for patients with severe renal impairment (CrCl <30 mL/min) or end-stage renal disease.
• Hepatic Impairment: No dosage adjustment for mild impairment. Reduce dose to 400 mg twice daily for moderate hepatic impairment (Child-Pugh B). Not recommended for severe hepatic impairment (Child-Pugh C).
• Adverse Reactions: Dose reductions (to 500 mg twice daily, then 400 mg twice daily, then 300 mg twice daily) and interruptions are required for management of hematologic toxicity and other severe side effects.

Clinical Efficacy and Research Results:

Rucaparib’s efficacy is supported by pivotal phase III trials (ARIEL3, TRITON2/3) with mature follow-up data and contemporary real-world analyses (2020-2025).

• Maintenance in Ovarian Cancer (ARIEL3): In patients with platinum-sensitive, recurrent ovarian cancer, rucaparib maintenance significantly improved median progression-free survival (PFS). For the BRCA-mutant cohort, median PFS was 16.6 months vs. 5.4 months with placebo. In the broader HRD-positive group, it was 13.6 months vs. 5.4 months.
• Treatment in BRCA-mutant mCRPC (TRITON2): In heavily pretreated patients, the confirmed objective response rate (ORR) was 43.5% per independent review. The median duration of response was not reached at the time of analysis, indicating durable responses.
• Overall Survival (OS) Signals: While not all trials have shown statistically significant OS benefits, consistent trends favoring PARP inhibitors like rucaparib are observed in subgroups, particularly those with BRCA mutations.

Safety Profile and Side Effects:

Black Box Warning:

• Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): Occurs in patients exposed to rucaparib and can be fatal. Monitor patients for hematologic toxicity.

Common Side Effects (>20%):

• Hematologic: Anemia, neutropenia, thrombocytopenia, increased ALT/AST.
• Gastrointestinal: Nausea, vomiting, constipation, diarrhea, abdominal pain, decreased appetite.
• Constitutional: Fatigue/asthenia.
• Dermatological: Rash.
• Respiratory: Dyspnea.

Management Strategies:

• Hematologic Toxicity: Obtain baseline CBC and monitor monthly. Manage anemia with dose interruption, reduction, and transfusions. Use growth factor support for neutropenia.
• Nausea/Vomiting: Prophylactic antiemetics are recommended. Manage breakthrough symptoms.
• Fatigue: Schedule rest periods, maintain mild activity, and ensure nutritional support.
• Elevated Liver Enzymes: Monitor LFTs monthly for the first 6 months. Manage with dose interruption/reduction.

Serious Adverse Events

• Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML).
• Severe Bone Marrow Suppression.
• Embryo-Fetal Toxicity.

Research Areas:

Rucaparib is the subject of extensive ongoing research (2020-2025) to expand its utility. Key areas include:

1. Combination Therapies: Investigating rucaparib in combination with immunotherapy (e.g., PD-1/PD-L1 inhibitors), anti-angiogenic agents (e.g., bevacizumab), and other targeted therapies across cancer types to overcome resistance and improve efficacy.
2. Earlier Lines of Therapy & New Indications: Evaluating its use in first-line ovarian cancer maintenance and treatment, and in other HRD-positive solid tumors (e.g., pancreatic, breast).
3. Predictive Biomarkers: Refining HRD testing and identifying new biomarkers beyond BRCA to better predict which patients will derive the most benefit.

Patient Management and Practical Recommendations:

Pre-treatment Tests:

• Homologous Recombination Deficiency (HRD) Testing: Tumor testing for BRCA1/2 mutations and genomic instability score (GIS), where applicable.
• Complete Blood Count (CBC) with differential.
• Comprehensive Metabolic Panel, including liver and renal function.
• Pregnancy Test for women of childbearing potential.

Precautions During Treatment:

• Hematologic Monitoring: Adhere to scheduled CBC monitoring (at least monthly).
• Contraception: Patients of reproductive potential must use effective contraception during and for at least 6 months after treatment.
• Drug Interactions: Avoid concomitant use of strong CYP3A inducers (e.g., rifampin) and moderate CYP3A inhibitors (e.g., fluconazole) if possible. Use caution with sensitive CYP1A2, CYP2C9, and CYP3A substrates.

Do’s and Don’ts:

• DO take your medication twice daily, about 12 hours apart, with or without food.
• DO report unusual bleeding/bruising, fatigue, shortness of breath, fever, or signs of infection immediately.
• DO attend all scheduled blood test appointments.
• DON’T become pregnant or father a child while on this medication and for specified periods after.
• DON’T start any new medications, supplements, or herbal products without consulting your oncology team.
• DON’T stop taking rucaparib unless directed by your doctor.

Legal Disclaimer:

This guide is for informational purposes for patients and healthcare professionals. It summarizes the FDA-approved use and key risks of rucaparib and is not a substitute for professional medical advice. Treatment decisions are highly individualized. Always consult your qualified healthcare provider for advice on your specific condition and treatment.